🔗 Share this article

While America continues making unprecedented adjustments to its vaccine recommendations, an unexpected name has surfaced unexpectedly: Høeg, a Danish American sports physician and epidemiologist who initially gained attention by casting doubt on Covid vaccinations during the global health crisis and has concentrated on possible fatalities following Covid immunization in her brief position at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Schedule

Health officials were set to announce sweeping changes to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, according to reports – a significant shift that would put the US out of alignment with a large portion of the global community with insufficient data for benefit. The planned update has been pushed back until the new year.

In place of the director of the vaccine center, Høeg is set to present at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Prasad solidify control at the FDA – and it points to a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has often pushed for ending some pediatric immunization guidelines in the US in order to be more in line with Denmark, a country with nationalized medicine and a number of inhabitants about the population of the state of Wisconsin.

In her initial public appearances, she has continued to focus on immunizations – usually the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Questions Over Background

The appointee has little discernible track record in drug development, regulation or administrative roles, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in leading a sizeable institution. She lacks background in drug approvals.”

Previous heads of the center would “be deeply familiar with legal statutes and the underlying principles of medication creation”, commented Janet Woodcock. “Objectively, she lacks the kind of background that previous people who ran CBER have had.”

The drug center has an enormous range of responsibilities at the agency, Woodcock emphasized.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes a multitude of generic medications. There’s a biosimilars program, OTC medication office and other areas, and each of these must be supervised,” Woodcock noted. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

Furthermore, a major leadership aspect to the role, which supervises more than 5,000 employees. “It is a huge management job, if you do it right,” she added.

Response and Disputed Programs

When asked about questions about Høeg’s qualifications and whether this appointment represents increased cooperation among agency officials on vaccines, a press secretary stated that the “questions are based on inaccurate presumptions”.

“Her experience matches the functions of her position,” the representative explained, citing the time Dr. Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg inherits the commissioner’s new expedited review system, a contentious one-day medication authorization process that reportedly troubled her predecessors. “By what process are these therapies being selected for this voucher program? Who makes the choices?” Howard said. “There’s a lot of lack of transparency occurring at the agency right now.”

In general, he stated, “the FDA seems to be moving towards more relaxed oversight of pharmaceuticals, except for shots.”

Documented Past Work on Vaccines

Regarding immunizations, Høeg has a clearer, if concerning, track record, Howard observe. She released a research paper using unconfirmed crowd-sourced reports to estimate the rate of heart inflammation after COVID-19 immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “wish list” for the current government included revising rules for recently developed shots and ending “non-essential” vaccines, she stated following the vote on a online show. At the FDA, Dr. Høeg has reportedly floated the idea of excluding teenage boys from receiving COVID-19 vaccinations.

“She’s an all-around ideologue who commences with her preconceived notions and tailors the evidence to retrofit the evidence in a highly deceptive, dishonest fashion,” Howard stated.

Gaining Influence and a “Push for Payback”

Høeg became part of other dissenters, {like|